Literature DB >> 25053934

Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma.

Inga A Laursen1, Lene Blou1, John S Sullivan2, Peter Bang1, Flemming Balstrup1, Gunnar Houen1.   

Abstract

BACKGROUND: The use of plasma-derived immunoglobulin G (IgG) is increasing, and the number of diseases, including immunodeficiencies, neurological diseases and autoimmune conditions, treated with intravenous IgG (IVIG) is expanding. Consequently, there is a great need for high-yield production processes for plasma-derived IgG. The aim of this work was to develop a high-yield process leading to a highly purified, liquid, ready-to-use IgG for intravenous use.
METHODS: Plasma from healthy, voluntary, non-remunerated donors was fractionated by ethanol precipitation. IgG was extracted from fraction II + III using a phosphate/acetate buffer, pH 4, and purified by chromatography.
RESULTS: Precipitation with 6% polyethylene glycol at pH 7 removed high molecular-weight contaminating proteins, aggregates and contaminating viruses. Ion exchange chromatography at pH 5.7 on serially connected anion and cation exchange columns allowed for elution of IgG from the cation exchange column in good yield and high purity. Further safety was achieved by solvent/detergent treatment and repeated ion exchange chromatography. The product consisted of essentially only IgG monomers and dimers, and had a high purity with very low levels of IgM and IgA.
CONCLUSION: A process providing highly purified IVIG in good yield was developed.

Entities:  

Keywords:  Chromatography; Immunoglobulin G; Intravenous; Polyethylene glycol precipitation

Year:  2014        PMID: 25053934      PMCID: PMC4086766          DOI: 10.1159/000357982

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  43 in total

1.  Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier.

Authors:  P KISTLER; H NITSCHMANN
Journal:  Vox Sang       Date:  1962 Jul-Aug       Impact factor: 2.144

Review 2.  Pharmacy considerations for the use of IGIV therapy.

Authors:  Sachin Shah
Journal:  Am J Health Syst Pharm       Date:  2005-08-15       Impact factor: 2.637

Review 3.  IGIV: contents, properties, and methods of industrial production--evolving closer to a more physiologic product.

Authors:  Turf D Martin
Journal:  Int Immunopharmacol       Date:  2005-12-13       Impact factor: 4.932

Review 4.  Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.

Authors:  Sophie Sibéril; SriRamulu Elluru; Vir-Singh Negi; Amal Ephrem; Namita Misra; Sandrine Delignat; Jagadeesh Bayary; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Transfus Apher Sci       Date:  2007-08-31       Impact factor: 1.764

Review 5.  Immunoglobulin subclasses and prophylactic use of immunoglobulin in immunoglobulin G subclass deficiency.

Authors:  T Söderström; R Söderström; A Enskog
Journal:  Cancer       Date:  1991-09-15       Impact factor: 6.860

Review 6.  Safety of intravenous immunoglobulin (IVIG) therapy.

Authors:  Uriel Katz; Anat Achiron; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2006-08-28       Impact factor: 9.754

7.  Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.

Authors:  M Ballow
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

8.  Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection.

Authors:  R B Moss; M A Carmack; S Esrig
Journal:  J Pediatr       Date:  1992-01       Impact factor: 4.406

Review 9.  Neonatal immune responses to coagulase-negative staphylococci.

Authors:  Tobias Strunk; Peter Richmond; Karen Simmer; Andrew Currie; Ofer Levy; David Burgner
Journal:  Curr Opin Infect Dis       Date:  2007-08       Impact factor: 4.915

10.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

View more
  3 in total

1.  Immunoglobulin G structure and rheumatoid factor epitopes.

Authors:  Sheila Lefoli Maibom-Thomsen; Nicole Hartwig Trier; Bettina Eide Holm; Kirsten Beth Hansen; Morten Ib Rasmussen; Anna Chailyan; Paolo Marcatili; Peter Højrup; Gunnar Houen
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

2.  Therapeutic Antibodies: An Overview.

Authors:  Gunnar Houen
Journal:  Methods Mol Biol       Date:  2022

3.  Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.

Authors:  Kevin Budding; Lill Eva Johansen; Inge Van de Walle; Kim Dijkxhoorn; Elisabeth de Zeeuw; Lauri M Bloemenkamp; Jeroen W Bos; Marc D Jansen; Chantall A D Curial; Karen Silence; Hans de Haard; Christophe Blanchetot; Liesbeth Van de Ven; Jeanette H W Leusen; R Jeroen Pasterkamp; Leonard H van den Berg; C Erik Hack; Peter Boross; W Ludo van der Pol
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.